Quick Comparison
| Gotu Kola | PEA (Palmitoylethanolamide) | |
|---|---|---|
| Half-Life | 2-4 hours (asiaticoside, madecassoside) | 1-2 hours (rapidly metabolized). Micronized forms have improved bioavailability |
| Typical Dosage | Standard: 500-1000 mg standardized extract daily (triterpenes: asiaticoside, madecassoside). Traditional dose: 1-2 grams dried herb as tea. ECa 233 is a well-studied standardized extract. Can be taken morning or evening — mild enough for bedtime use. | Standard: 300-1200 mg daily in 2-3 divided doses. Start at 600 mg daily. Micronized or ultra-micronized (um-PEA) forms have much better absorption. For chronic pain: 600 mg twice daily. For neuroinflammation: 400-600 mg twice daily. Effects build over 2-4 weeks. |
| Administration | Oral (capsules, extract, tea, tincture). ECa 233 standardized extract for consistent dosing. | Oral (capsules, powder). Micronized (m-PEA) or ultra-micronized (um-PEA) forms preferred for bioavailability. |
| Research Papers | 9 papers | 10 papers |
| Categories |
Mechanism of Action
Gotu Kola
Triterpene saponins (asiaticoside, madecassoside, asiatic acid, madecassic acid) are the primary bioactives. They increase BDNF expression in the hippocampus via CREB and ERK/MAPK pathways, promoting neuroplasticity, synaptogenesis, and memory formation. They enhance collagen type I synthesis through stimulation of fibroblasts and improve microcirculation via VEGF and angiopoietin modulation. Anxiolytic effects occur through positive allosteric modulation of GABA-A receptors (possibly at the benzodiazepine or neurosteroid site) and reduction of acoustic startle response (amygdala modulation). Gotu kola inhibits acetylcholinesterase (AChE), mildly increasing synaptic acetylcholine. Anti-inflammatory effects come from NF-kB inhibition (IkB stabilization) and TNF-alpha suppression. Asiatic acid may also activate PPAR-gamma.
PEA (Palmitoylethanolamide)
PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.
Risks & Safety
Gotu Kola
Common
Very well-tolerated. Mild GI upset, drowsiness.
Serious
Rare hepatotoxicity reported — avoid with liver disease and limit use to 6-week cycles.
Rare
Headache, dizziness, skin sensitivity to sunlight.
PEA (Palmitoylethanolamide)
Common
Very well-tolerated — rare side effects. Mild GI discomfort.
Serious
None documented. Over 30 clinical trials confirm excellent safety profile.
Rare
Skin rash.
Full Profiles
Gotu Kola →
Centella asiatica is an Ayurvedic and Chinese medicine herb known as the 'herb of longevity.' It has been used for centuries to enhance memory, promote wound healing, and reduce anxiety. Modern research confirms it increases BDNF, enhances collagen synthesis, improves microcirculation, and has anxiolytic effects. Unlike most adaptogens, gotu kola has clinical evidence for improving memory and attention in healthy adults.
PEA (Palmitoylethanolamide) →
An endogenous fatty acid amide produced naturally in the body in response to pain and inflammation. PEA activates PPAR-alpha receptors and indirectly enhances endocannabinoid signaling without binding to cannabinoid receptors. It has strong evidence for neuropathic pain, neuroinflammation, and neuroprotection. Unlike anti-inflammatory drugs, it resolves inflammation rather than merely suppressing it.